1 – 35 of 35
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Use of Linked Nordic Registries for Population Studies in Hematologic Cancers : The Case of Multiple Myeloma
(
- Contribution to journal › Article
- 2022
-
Mark
Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls
(
- Contribution to journal › Letter
- 2021
-
Mark
Germline variants at SOHLH2 influence multiple myeloma risk
(
- Contribution to journal › Article
- 2020
-
Mark
Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels
(
- Contribution to journal › Letter
-
Mark
Outcome and characteristics of non-measurable myeloma : A cohort study with population-based data from the Swedish Myeloma Registry
(
- Contribution to journal › Article
- 2019
-
Mark
Sequence variation at the MTHFD1L-AKAP12 and FOPNL loci does not influence multiple myeloma survival in Sweden
(
- Contribution to journal › Letter
- 2018
-
Mark
The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression
(
- Contribution to journal › Article
- 2017
-
Mark
Direct evidence for a polygenic etiology in familial multiple myeloma
(
- Contribution to journal › Article
-
Mark
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors : a multicenter IMWG study
(
- Contribution to journal › Article
-
Mark
Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register
(
- Contribution to journal › Article
- 2016
-
Mark
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma
(
- Contribution to journal › Article
-
Mark
Management of relapsed multiple myeloma: Recommendations of the international myeloma working group.
(
- Contribution to journal › Scientific review
-
Mark
Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study.
(
- Contribution to journal › Article
- 2015
-
Mark
Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B.
(
- Contribution to journal › Article
-
Mark
Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma.
(
- Contribution to journal › Article
-
Mark
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
(
- Contribution to journal › Article
-
Mark
Population-based study on the impact of the familial form of Waldenström macroglobulinemia on overall survival.
(
- Contribution to journal › Letter
-
Mark
Does Low-Molecular-Weight Heparin Influence the Antimyeloma Effects of Thalidomide? A Retrospective Analysis of Data from the GIMEMA, Nordic and Turkish Myeloma Study Groups
(
- Contribution to journal › Article
-
Mark
Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease
(
- Contribution to journal › Letter
-
Mark
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.
(
- Contribution to journal › Article
-
Mark
The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
(
- Contribution to journal › Article
- 2014
-
Mark
Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin.
(
- Contribution to journal › Article
-
Mark
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
(
- Contribution to journal › Scientific review
-
Mark
Elevated risk of venous but not arterial thrombosis in Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma
(
- Contribution to journal › Article
-
Mark
Robust isolation of malignant plasma cells in multiple myeloma.
(
- Contribution to journal › Article
- 2013
-
Mark
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
(
- Contribution to journal › Article
- 2008
-
Mark
A Randomised Placebo Controlled Study With Melphalan/Prednisone Vs Melphalan/Prednisone/Thalidomide: Quality Of Life And Toxicity
2008) 13th Congress of the European-Hematology-Association In Haematologica-The Hematology Journal 93. p.0209-0209(
- Contribution to journal › Published meeting abstract
- 2004
-
Mark
Early response predicts thalidomide efficiency in patients with advanced multiple myeloma
(
- Contribution to journal › Article
- 2003
-
Mark
A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences.
(
- Contribution to journal › Article
-
Mark
Radiation therapy dose delivery
(
- Contribution to journal › Article
- 2002
-
Mark
Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor
(
- Contribution to journal › Article
- 1993
-
Mark
Clinical impact of breakpoint position within M-bcr in chronic myeloid leukemia
(
- Contribution to journal › Article
- 1978
-
Mark
Non-secretory or low-secretory myeloma with intracellular kappa chains. Report of six cases and review of the literature
(
- Contribution to journal › Article
- 1977
-
Mark
Expression of protein HC on the plasma membrane of different human cell types
(
- Contribution to journal › Article
- 1976
-
Mark
Immunofluorescent demonstration of the presence of protein HC on the surface of human lymphocytes
(
- Contribution to journal › Article